Medtronic (NYSE: MDT) today announced new data demonstrating the health economic benefits of its MiniMed 780G system.

Medtronic announced the full U.S. launch for its Instinct sensor, made by Abbott, paired with the MiniMed 780G pump.

Medtronic has announced the broad U.S. commercial launch of the MiniMed 780G insulin pump system integrated with the Instinct sensor, made by Abbott and designed exclusively for MiniMed systems.

The partnership is the first time Medtronic has integrated its insulin pumps with a sensor developed outside of the company.

Available in Europe since 2020, this new system delivers the strongest clinical outcomes and best user experience to-date within the Medtronic family of pumps "Mealtimes prove to be one of the biggest ...

Medtronic plc’s MDT most advanced automated insulin delivery (AID) system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as part of ...

Late last week, medical device giant Medtronic received FDA approval for its MiniMed 780G system. The device is an insulin pump that automatically adjusts and corrects type 1 diabetes patients’ ...

After a long delay, the U.S. Food and Drug Administration has approved Medtronic's MiniMed 780G device, the company's next-generation insulin pump. Medtronic's diabetes division has been under a ...

Medtronic plc MDT recently announced the receipt of the CE Mark for its next generation closed loop insulin pump system, MiniMed 780G, for the treatment of type 1 diabetes in the age range of 7 to 80 ...

It’s notoriously difficult to manage blood sugar levels in children and teenagers with Type 1 diabetes because of their high activity levels, constantly fluctuating hormones and ongoing growth and ...

Medtronic says it has promising data on the effectiveness of its next-generation insulin pump from patients in Europe and Chile. The MiniMed 780G insulin pump, which was cleared in 2020 for use in ...